{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:13:00Z","timestamp":1793743980953,"version":"4.6.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":193,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Sphingosine 1-phosphate receptor modulators have been associated with an increased risk of macular edema. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We report the proportions and incidence rates (per 100 patient-years of exposure) of Macular edema and other ocular adverse events in the etrasimod clinical program, including patients with ulcerative colitis, Crohn\u2019s disease, eosinophilic esophagitis, alopecia areata, and atopic dermatitis. Ulcerative colitis data were analyzed in 2\u00a0cohorts: Placebo-controlled ulcerative colitis and All ulcerative colitis (comprising the Placebo-controlled ulcerative colitis cohort plus open-label extension studies).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the Placebo-controlled ulcerative colitis cohort, Macular edema was reported in 2\u00a0patients receiving etrasimod (0.3%; incidence rate: 0.70) and 1\u00a0receiving placebo (0.3%; incidence rate: 0.84). In the All ulcerative colitis cohort, 1\u00a0patient (0.1%; incidence rate: 0.13) receiving etrasimod reported 2\u00a0events of Cystoid macular edema. All events were nonserious, and 1\u00a0led to treatment discontinuation. No events of Macular edema were reported in other conditions. Nine and 4\u00a0patients receiving etrasimod reported Vision blurred and Visual impairment adverse events, respectively. All events were nonserious and most did not require any intervention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Macular edema and other ocular events were uncommon in patients treated with etrasimod across multiple conditions. Incidence of Macular edema was comparable with placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials.gov identifiers<\/jats:title>\n                  <jats:p>NCT02447302; NCT03945188; NCT03996369; NCT02536404; NCT03950232; NCT04176588; NCT04173273; NCT04682639; NCT04556734; NCT04162769<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae173","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T10:07:36Z","timestamp":1732270056000},"source":"Crossref","is-referenced-by-count":7,"title":["Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program"],"prefix":"10.1093","volume":"19","author":[{"given":"Marla C","family":"Dubinsky","sequence":"first","affiliation":[{"name":"Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Wu","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoibhinn","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Pfizer Ltd , Sandwich ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Lazin","sequence":"additional","affiliation":[{"name":"Pfizer AG , Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Goetsch","sequence":"additional","affiliation":[{"name":"Pfizer AG , Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Branquinho","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Modesto","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"IBD Unit, IRCCS Humanitas Research Hospital , Rozzano, Milan ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"2025060310593641700_CIT0001","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.3748\/wjg.v23.i32.5836","article-title":"Ophthalmic manifestations in patients with inflammatory bowel disease: a review","volume":"23","author":"Troncoso","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2025060310593641700_CIT0002","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/cells13020142","article-title":"Ophthalmological manifestations in inflammatory bowel diseases: keep an eye on it","volume":"13","author":"Migliorisi","year":"2024","journal-title":"Cells"},{"key":"2025060310593641700_CIT0003","doi-asserted-by":"crossref","first-page":"e052833","DOI":"10.1136\/bmjopen-2021-052833","article-title":"Risk of a subsequent diagnosis of inflammatory bowel disease in subjects with ophthalmic disorders associated with inflammatory bowel disease: a retrospective cohort analysis of UK primary care data","volume":"12","author":"King","year":"2022","journal-title":"BMJ Open"},{"key":"2025060310593641700_CIT0004","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","article-title":"Mechanisms of macular edema: beyond the surface","volume":"63","author":"Daruich","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"2025060310593641700_CIT0005","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.3390\/jcm12155014","article-title":"Efficacy and safety of S1P1 receptor modulator drugs for patients with moderate-to-severe ulcerative colitis","volume":"12","author":"Bencardino","year":"2023","journal-title":"J Clin Med"},{"key":"2025060310593641700_CIT0006","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/14656566.2022.2071605","article-title":"An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis","volume":"23","author":"Rowan","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"2025060310593641700_CIT0007","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1124\/jpet.118.254268","article-title":"The selective sphingosine 1-phosphate receptor modulator etrasimod regulates lymphocyte trafficking and alleviates experimental colitis","volume":"369","author":"Al-Shamma","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"2025060310593641700_CIT0008","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2147\/OPTH.S4033","article-title":"Cystoid macular edema","volume":"2","author":"Rotsos","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"2025060310593641700_CIT0009","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2025060310593641700_CIT0010","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"2025060310593641700_CIT0011","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2025060310593641700_CIT0012","doi-asserted-by":"crossref","first-page":"i764","DOI":"10.1093\/ecco-jcc\/jjac190.0762","article-title":"P632 Etrasimod induction therapy in moderately to severely active Crohn\u2019s disease: results from a phase 2, randomised, double-blind substudy","volume":"17","author":"D\u2019Haens","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2025060310593641700_CIT0013","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.14309\/01.ajg.0000951460.86738.5a","article-title":"S455 Efficacy and safety of the selective sphingosine 1-phosphate receptor modulator, etrasimod, in adult patients with eosinophilic esophagitis: primary results from the phase 2 VOYAGE study","volume":"118","author":"Dellon","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2025060310593641700_CIT0014","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/jdv.18914","article-title":"Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)","volume":"37","author":"Silverberg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025060310593641700_CIT0015","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"2025060310593641700_CIT0016","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","article-title":"Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension","volume":"18","author":"Danese","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2025060310593641700_CIT0017","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"2025060310593641700_CIT0018","doi-asserted-by":"crossref","first-page":"102125","DOI":"10.1016\/j.msard.2020.102125","article-title":"Real-world incidence of fingolimod-associated macular oedema","volume":"42","author":"Goh","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2025060310593641700_CIT0019","author":"European Medicines Agency","year":"2024"},{"key":"2025060310593641700_CIT0020","author":"US Food and Drug Administration","year":"2024"},{"key":"2025060310593641700_CIT0021","author":"US Food and Drug Administration","year":"2024"},{"key":"2025060310593641700_CIT0022","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae173\/61006861\/jjae173.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjae173\/61006861\/jjae173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjae173\/61006861\/jjae173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T14:59:47Z","timestamp":1748962787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjae173\/7906855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae173","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,11,22]]},"article-number":"jjae173"}}